课题基金 / 基金详情

Beta blockers, dialyzability and outcomes

Beta blockers, dialyzability and outcomes
β 受体阻滞剂、透析性和结果
批准号：
225022
负责人：
Weir Matthew A
金额：
$4.37万
依托单位：
London Health Sciences Centre Res. Inc. (Ont.)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2011
资助国家：
加拿大
项目状态：
已结题
起止时间：
2011-03-01 至 2012-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=225022&lang=en
关键词：
Beta Blockers Health Care Databases Hemodialysis Outcomes

项目摘要

项目成果

Weir Matthew A的其他基金

相似基金

相关文献

中文摘要
翻译
肾功能衰竭的人要接受血液透析治疗，这是一种人造肾脏机器。心脏病在这些患者中很常见。β受体阻滞剂是一组已知可以帮助心脏病发作的人的药物。那些拿走的人
英文摘要
People whose kidneys have failed are treated with hemodialysis, an artificial kidney machine. Heart attacks are common in these patients. Beta blockers are a group of medications that are known to help people who have had a heart attack. Those who take be
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Filling Knowledge Gaps for the Success of Ontario Renal Plan 3
Filling Knowledge Gaps for the Success of Ontario Renal Plan 3
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease-1 (MPAC-CKD-1)
海外基金